Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Lucentis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lucentis was produced by Novartis and Roche.

NICE no for new eye disease drug

NICE no for new eye disease drug drugs on the market, including Novartis/Roche's Lucentis (ranibizumab) and Bayer/Regeneron's Eylea (aflibercept).

Eylea growth closes the gap with Lucentis

Eylea growth closes the gap with Lucentis Armed with new indications such as diabetic macular edema (DME), Eylea (aflibercept) can now compete with rival Lucentis (ranibizumab) sold by Roche and Novartis on a more equal footing and sales ... Lucentis still selling more than Eylea by value but is

Medius Deal Watch table for February 2015

Medius Deal Watch table for February 2015 Majority acquisition. 380. Pfenex/ Hospira. PF582 -  LUCENTIS biosimilar candidate - wet age-related macular degeneration, diabetic macular oedema.

Roche maintains top place in biologic sales

Roche maintains top place in biologic sales It also has a strong showing from across its drug portfolio, with its breast cancer drug Herceptin (trastuzumab) bringing in more than CHF6bn last year, with eye drug Lucentis (ranibizumab) and

Trials of Roche's new blindness candidate now underway

Trials of Roche's new blindness candidate now underway Roche and partner Novartis already market their vascular endothelial growth factor (VEGF) inhibitor Lucentis (ranibizumab) for the wet or neovascular form of AMD, as well as macular oedema caused by diabetes ... While multiple therapies exist for wet

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics